← Back to Search

Monoclonal Antibodies

ADX-097 for Immunoglobulin A Nephropathy

Phase 2
Recruiting
Research Sponsored by Q32 Bio Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Key
Male or female participants aged ≥18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 42 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new drug called ADX-097 in male and female participants aged 18 years or older who have certain kidney diseases. The study will look at the safety, how the drug

Who is the study for?
This trial is for adults over 18 with certain kidney conditions: IgAN, LN, or C3G. They should have protein in their urine and a minimum kidney function level. Participants must be on stable doses of specific medications for at least 12 weeks before the study starts.
What is being tested?
The trial tests ADX-097, administered subcutaneously (under the skin), to assess its safety and effectiveness in treating IgAN, LN, or C3G. It will also look at how the body processes the drug.
What are the potential side effects?
Potential side effects are not explicitly listed but may include reactions at injection sites, changes in kidney function tests, allergic responses or other immune system-related events.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been on a stable dose of a RAAS inhibitor for at least 12 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~42 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 42 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events (AEs) to evaluate the safety of ADX-097
Secondary study objectives
Change from baseline in estimated glomerular filtration rate (eGFR)
Change from baseline in urine protein-to-creatinine ratio (uPCR)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open LabelExperimental Treatment1 Intervention
Subcutaneous Infusions

Find a Location

Who is running the clinical trial?

Q32 Bio Inc.Lead Sponsor
3 Previous Clinical Trials
184 Total Patients Enrolled
~20 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top